A director at Argen X SE sold 8,794 shares at 768.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
argenx Announces Results of Extraordinary General Meeting of Shareholders November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025. The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majority, with 91.1% of shar...
argenx' 3Q25 numbers came in solid with Vyvgart sales of $ 1.13b, delivering another beat (approx. 6.8%) on company compiled CSS ($ 1,054.8m). Product revenue consensus for FY25 currently stands at $ 3.93b, which is well within reach as PFS continues to contribute to the launch momentum. argenx reached operating profitability for the 5th consecutive quarter despite a 40% increase in opex. ACCUMULATE maintained.
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update $1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving th...
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE for at least 4 weeks Real world data show >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit October 29, ...
Nyrstar NV: Further update on decision of the FSMA Sanctions Committee of 26 September 2025 Regulated Information – inside information Nyrstar NV: Further update on decision of the FSMA Sanctions Committee of 26 September 2025 28 October 2025 at 07:00 CET The Sanctions Committee of the Belgian Financial Services and Markets Authority (FSMA) issued a decision on 26 September 2025 in relation to the information disclosure by Nyrstar NV (the “Company”) on 30 October 2018. As noted in its press release of 28 September 2025 (), the Company indicated that it would carefully review this decisio...
Nyrstar NV: verdere update over beslissing van de Sanctiecommissie van de FSMA van 26 september 2025 Gereglementeerde informatie - Voorwetenschap Nyrstar NV: verdere update over beslissing van de Sanctiecommissie van de FSMA van 26 september 2025 28 October 2025 om 07u00 CET De Sanctiecommissie van de Belgische Autoriteit voor Financiële Diensten en Markten (FSMA) deed op 26 september 2025 een uitspraak over de informatieverstrekking van Nyrstar NV (de “Vennootschap”) op 30 oktober 2018. Zoals toegelicht in haar persbericht van 28 september 2025 (), zou de Vennootschap deze beslissing aa...
Nyrstar NV: Update on decision of the FSMA Sanctions Committee of 26 September 2025 Regulated Information – inside information Nyrstar NV: Update on decision of the FSMA Sanctions Committee of 26 September 2025 26 October 2025 at 22:30 CET The Sanctions Committee of the Belgian Financial Services and Markets Authority (FSMA) issued a decision on 26 September 2025 in relation to the information disclosure by Nyrstar NV (the “Company”) on 30 October 2018. The Company provided a description of this decision in its press release of 28 September 2025 (). On the evening of Friday 24 October 2...
Nyrstar NV: Update over beslissing van de Sanctiecommissie van de FSMA van 26 september 2025 Gereglementeerde informatie - Voorwetenschap Nyrstar NV: Update over beslissing van de Sanctiecommissie van de FSMA van 26 september 2025 26 October 2025 om 22u30 CET De Sanctiecommissie van de Belgische Autoriteit voor Financiële Diensten en Markten (FSMA) deed op 26 september 2025 een uitspraak over de informatieverstrekking van Nyrstar NV (de “Vennootschap”) op 30 oktober 2018. De Vennootschap heeft die uitspraak toegelicht in haar persbericht van 28 september 2025 (). De Vennootschap heeft o...
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 October 23, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.